

## **Massachusetts Department of Public Health Standing Order 2025-01**

### **Standing Order for Dispensing and Administration of COVID-19 Vaccine: 2025-2026**

This standing order authorizes qualified pharmacy personnel pursuant to 105 CMR 700.004(B)(6) to dispense and administer COVID-19 vaccine in Massachusetts to all eligible persons as described below.

#### **Procedure**

1) Screen for Contraindications and Precautions.

Contraindications:

- A severe allergic reaction (e.g., anaphylaxis) after a previous dose of the COVID-19 vaccine or to a component of the COVID-19 vaccine

Precautions:

- A diagnosed non-severe allergy to a component of the COVID-19 vaccine.
- Non-severe, immediate (onset less than 4 hours) allergic reaction after administration of a previous dose of one COVID-19 vaccine type, if receiving the same vaccine type.
- Myocarditis or pericarditis within 3 weeks after a dose of any COVID-19 vaccine.
- Moderate to severe acute illness, with or without fever.

2) Provide Vaccine Information Statements.

3) Prepare to Administer Vaccine.

- Verify that the label on the vaccine states 2025-2026 Formula.
- Choose the needle gauge, needle length, and injection site.

4) Administer COVID-19 Vaccine

#### **For intramuscular administration**

- MNEXSPIKE (COVID-19 Vaccine, mRNA) injectable suspension, 2025-2026 Formula

Dispense single 0.2 mL dose for:

- Individuals 12 years of age and older
- For individuals previously vaccinated with any COVID-19 vaccine, administer the dose of MNEXSPIKE at least 3 months after the last dose of COVID-19 vaccine

Directions for use: Administer MNEXSPIKE as a single 0.2 mL dose

#### **OR**

- SPIKEVAX (COVID-19 Vaccine, mRNA) injectable suspension, 2025-2026 Formula

a. Individuals 5 years of age through 11 years of age

Dispense single 0.25 mL dose, irrespective of COVID-19 vaccination status.

- For individuals previously vaccinated with any COVID-19 vaccine, administer the dose  $\geq 2$  months after the last dose of COVID-19 vaccine

Direction for use: Administer SPIKEVAX 0.25 mL dose

#### **OR**

b. Individuals 12 years of age and older

Dispense single 0.5 mL dose, irrespective of COVID-19 vaccination status.

- For individuals previously vaccinated with any COVID-19 vaccine, administer the dose  $\geq 2$  months after the last dose of COVID-19 vaccine

Direction for use: Administer SPIKEVAX 0.5 mL dose

**OR**

- COMIRNATY (COVID-19 Vaccine, mRNA) injectable suspension, 2025-2026 Formula
  - a. Individuals 5 years of age through 11 years of age
    - Dispense single 0.3 mL dose supplied in vials with blue caps and labeled with blue borders
      - For individuals previously vaccinated with any COVID-19 vaccine, administer the dose at least 2 months after the last dose of COVID-19 vaccine
    - Directions for use: Administer COMIRNATY as a single 0.3 mL dose
  - OR**
  - b. Individuals 12 years of age and older
    - Dispense single 0.3 mL dose supplied in prefilled syringes labeled with gray borders
      - For individuals previously vaccinated with any COVID-19 vaccine, administer the dose at least 2 months after the last dose of COVID-19 vaccine
    - Direction for use: Administer COMIRNATY as a single 0.3 mL dose

**OR**

- NUVAXOVID (COVID-19 Vaccine, Adjuvanted) injectable suspension, 2025-2026 Formula
  - Dispense single 0.5 mL dose for:
    - Individuals 12 years of age and older
    - For individuals previously vaccinated with any COVID-19 vaccine, administer the dose of NUVAXOVID at least 2 months after the last dose of COVID-19 vaccine
  - Directions for use: Administer NUVAXOVID as a single 0.5 mL dose

- 5) Document the Vaccination.
- 6) Be Prepared to Manage Medical Emergencies.
- 7) Report Adverse Events to the Vaccine Adverse Event Reporting System (VAERS).

  
Physician's Signature

**September 19, 2025**

---

**Robert H Goldstein, MD, PhD**  
**MA 261463**  
**NPI Number: 1487918850**

**Physician's Name and MA License No. (print legibly)**